ClinicalTrials.gg
Status unknownNCT05409690Updated Jun 8, 2022

Renal Arterial Resistive Index for Differential Diagnosis of Acute Kidney Injury

An observational study in Acute Kidney Injury, sponsored by Ankara Diskapi Training and Research Hospital. Status unknown at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-08.

Sponsored by Ankara Diskapi Training and Research Hospital · Observational

How we know

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies in Acute Kidney Injury with a site in Turkey — 21 open to participants now, 22 under way, none of them phase 3. Acute Kidney Injury · Turkey.

Planned enrollment
71st of 73
30 · median 130
Started
2022
with 8 others
Observational
73 of 90
15 open now
Registered
25th of 90
by date
Lead sponsor
2 of 90
Ankara Diskapi Training and Research Hospital

Among the 90 studies in Acute Kidney Injury with a site in Turkey, this one is the 71st largest by planned enrollment of the 73 observational ones that give a count, is one of 9 that started in 2022, is one of 73 observational ones, and was the 25th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

21 of the 90 studies in Acute Kidney Injury with a site in Turkey are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Acute Kidney Injury with a site in Turkey, or all of them as a file.
02

Study summary

early differential diagnosis of anticipated acute kidney injury via ultrasound renal resistive index calculation

Read the detailed description

acute kidney injury is a common clinical syndrome introducing to emergency services with varying symptoms. acute kidney injury is divided into 3 subgroups: prerenal, renal and postrenal. there is not any certain laboratory or imaging modality for early detection of injury's type. calculation of renal resistive index with doppler ultrasound at emergency setting can be helpful for early detection of etiology of acute kidney injury subgroup.patient will be selected according to clinical status and detailed history and laboratory parameters.renal resistive index will we calculated with doppler ultrasound of arcuate and interlober arteries of kidneys. resistive index values of acute kidney injury patients will be compared depending on further tests and resistive indexes of suggestive etiologies will be compared according to final diagnosis.

03

Conditions studied

  • Acute Kidney Injury

Browse trials for

Keywords

  • acute kidney injury
  • renal resistive index
  • doppler ultrasound
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patient administering to emergency service with acute kidney injury independent of etiology

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age over 18
  2. patient with acute kidney injury diagnosed according to KDIGO, AKIN or RIFLE criteria

Exclusion criteria

Exclusion Criteria:

  1. end stage kidney disease
  2. patients receiving renal replacement treatment
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. increased resistive index

    differential diagnosis of acute kidney injury using renal doppler ultrasound and resistive index and comparison of subgroups

    Time frame: time spent at emergency service until renal doppler is done and resisitive index is calculated (6 hours)

Secondary outcomes

  1. mortality

    mortality

    Time frame: mortality at 7 days

  2. mortality

    mortality

    Time frame: mortality at 28 days

07

Study locations

1 of 1 sites recruiting
  • Diskapi Research and Training Hospital
    Ankara, 06110, Turkey
    Recruiting
    • bedriye müge sönmez, assoc. prof · Contactmugesonmez06@yahoo.com · +905055823208
    • bedriye müge sönmez, assoc. prof · Principal investigator
    • gülşen çığşar, assoc. prof · Sub investigator
    • mustafa arslan, resident · Sub investigator
    • melih gökçimen, resident · Sub investigator
    • ilker şirin, resident · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Nov 2022, 6 months after the start.

Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 6 months is below that.

Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2022
First posted
Jun 8, 2022
StartActual
May 10, 2022
Primary completionEst.
Nov 10, 2022
CompletionEst.
Nov 10, 2022
Last update
Jun 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05409690
Lead sponsor
Ankara Diskapi Training and Research Hospital
Responsible party
Bedriye Muge Sonmez (asossicated professor, Ankara Diskapi Training and Research Hospital) — Principal investigator
First posted
Jun 8, 2022
Start date
May 10, 2022
Primary completion
Nov 10, 2022 (estimated)
Completion
Nov 10, 2022 (estimated)
Last update
Jun 8, 2022

Study contacts

bedriye müge sönmez, assoc. prof.
Contact
mugesonmez06@yahoo.com
00905055823208
gülşen çığşar, assoc. prof.
Contact
gulakcay@yahoo.com
00905052874949

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion